Latigo Biotherapeutics is a private, early-stage biotechnology company discovering and developing the next generation of non-opioid medicines for pain and pain-related syndromes to transform the lives of patients. Latigo has a robust pipeline, is well-funded by blue chip investors, and has a highly successful management team and Board of Directors. The company was founded in 2019 and is based on Thousand Oaks, CA . We are science-based, patient-focused, and forward-thinking.